Does PRRT with standard activities of (177)Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors

BACKGROUND: Peptide receptor radionuclide therapy (PRRT) with (177)Lu-[DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate) is generally performed using a fixed activity of 7.4 GBq (200 mCi) per course bound to 180 to 300 μg of the peptide. While this single activity may lead to suboptimal radiation doses...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Sabet, Amir, Nagarajah, James, Dogan, Ahmet Semih, Biersack, Hans-Jürgen, Sabet, Amin, Guhlke, Stefan, Ezziddin, Samer
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer 2013
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3877953/
https://ncbi.nlm.nih.gov/pubmed/24369053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2191-219X-3-82
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi